Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Author(s) -
Bengt Fellström,
Alan G. Jardine,
Roland E. Schmieder,
Hallvard Holdaas,
Kym M. Bannister,
Jaap J. Beutler,
DongWan Chae,
Alejandro Chevaile,
Stuart M. Cobbe,
Carola GrönhagenRiska,
José J. De Lima,
R. Lins,
Gert Mayer,
Alan W. McMahon,
HansHenrik Parving,
Giuseppe Remuzzi,
Ola Samuelsson,
S. Sonkodi,
Gultekin Süleymanlar,
Dimitrios Tsakiris,
Vladimı́r Tesař,
Vasil Todorov,
Andrzej Więcek,
Rudolf P. Wüthrich,
Mattis Gottlow,
Eva Johnsson,
Faı̈ez Zannad
Publication year - 2009
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0810177
Subject(s) - rosuvastatin , medicine , hazard ratio , hemodialysis , myocardial infarction , placebo , rosuvastatin calcium , clinical endpoint , confidence interval , incidence (geometry) , randomized controlled trial , cardiology , physics , alternative medicine , pathology , optics
Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been proved.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom